ESC 2013:运动诱导的循环高敏肌钙蛋白T变化对稳定性胸痛患者的诊断价值

2013-09-03 MedSci MedSci原创

  背景:心肌肌钙蛋白T(cTnT)是心肌坏死的标志物,但其是否是可逆性缺血的标志物尚存争议。该研究旨在评估测定运动试验前及运动试验后20小时的cTnT能否改善对稳定性胸痛患者的诊断评估。   方法:入选157例可疑冠状动脉疾病(CAD)患者,收集其限制性运动试验前及试验后20小时的血样。采用 CT冠脉造影和/或冠脉造影评估冠状动脉的解剖情况,并将患者分为以下四组:①无钙化组(n=65),②钙

  背景:心肌肌钙蛋白T(cTnT)是心肌坏死的标志物,但其是否是可逆性缺血的标志物尚存争议。该研究旨在评估测定运动试验前及运动试验后20小时的cTnT能否改善对稳定性胸痛患者的诊断评估。

  方法:入选157例可疑冠状动脉疾病(CAD)患者,收集其限制性运动试验前及试验后20小时的血样。采用 CT冠脉造影和/或冠脉造影评估冠状动脉的解剖情况,并将患者分为以下四组:①无钙化组(n=65),②钙化但无狭窄组(n=51),③CAD冠脉狭窄 50%~70%组(n=16),④CAD冠脉狭窄≥70%组(n=25)。

  结果:与非CAD者相比,CAD患者基线平均cTnT水平更高(6.39 pg/ml vs. 3.00 pg/ml,P<0.0001),运动后cTnT水平更易增加(70.7% vs. 27.6%,P<0.0001)。与单用运动试验相比,运动试验与cTnT反应联用诊断冠脉狭窄≥50%CAD的AUC更大(0.70 vs. 0.60,P=0.03),敏感性由43.9%增加至85.4%,重新分类指数(NRI)为19%(P=0.02)。联合试验对明显CAD(冠脉狭窄≥70%)的阴性预测价值高达97.1%。

  结论:在稳定性胸痛患者中,运动诱导的cTnT增加与冠脉狭窄具有相关性。在运动试验的基础上,于运动试验前及试验后20小时测定cTnT水平有助于改善诊断评估水平。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1721653, encodeId=45aa1e216534c, content=<a href='/topic/show?id=39d6915e9bf' target=_blank style='color:#2F92EE;'>#诊断价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91579, encryptionId=39d6915e9bf, topicName=诊断价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c7d33065043, createdName=medscijoin, createdTime=Thu Apr 10 11:53:00 CST 2014, time=2014-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900415, encodeId=16751900415c1, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Oct 27 22:53:00 CST 2013, time=2013-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6310, encodeId=58de631046, content=不错哈,飘过, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq6oFDfbfbCR2QaXr43JZleficjricO9bqaynTice57nB7xlLgg7tXtX5Y7RdTrC6pjWbuiaJ5RLVvib8w/132, createdBy=0c4390618, createdName=qingqingye, createdTime=Fri Nov 29 23:48:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569108, encodeId=78f3156910806, content=<a href='/topic/show?id=2651810889c' target=_blank style='color:#2F92EE;'>#肌钙蛋白T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81088, encryptionId=2651810889c, topicName=肌钙蛋白T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f7f15492758, createdName=huangdf, createdTime=Thu Sep 05 12:53:00 CST 2013, time=2013-09-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1721653, encodeId=45aa1e216534c, content=<a href='/topic/show?id=39d6915e9bf' target=_blank style='color:#2F92EE;'>#诊断价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91579, encryptionId=39d6915e9bf, topicName=诊断价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c7d33065043, createdName=medscijoin, createdTime=Thu Apr 10 11:53:00 CST 2014, time=2014-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900415, encodeId=16751900415c1, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Oct 27 22:53:00 CST 2013, time=2013-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6310, encodeId=58de631046, content=不错哈,飘过, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq6oFDfbfbCR2QaXr43JZleficjricO9bqaynTice57nB7xlLgg7tXtX5Y7RdTrC6pjWbuiaJ5RLVvib8w/132, createdBy=0c4390618, createdName=qingqingye, createdTime=Fri Nov 29 23:48:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569108, encodeId=78f3156910806, content=<a href='/topic/show?id=2651810889c' target=_blank style='color:#2F92EE;'>#肌钙蛋白T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81088, encryptionId=2651810889c, topicName=肌钙蛋白T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f7f15492758, createdName=huangdf, createdTime=Thu Sep 05 12:53:00 CST 2013, time=2013-09-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1721653, encodeId=45aa1e216534c, content=<a href='/topic/show?id=39d6915e9bf' target=_blank style='color:#2F92EE;'>#诊断价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91579, encryptionId=39d6915e9bf, topicName=诊断价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c7d33065043, createdName=medscijoin, createdTime=Thu Apr 10 11:53:00 CST 2014, time=2014-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900415, encodeId=16751900415c1, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Oct 27 22:53:00 CST 2013, time=2013-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6310, encodeId=58de631046, content=不错哈,飘过, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq6oFDfbfbCR2QaXr43JZleficjricO9bqaynTice57nB7xlLgg7tXtX5Y7RdTrC6pjWbuiaJ5RLVvib8w/132, createdBy=0c4390618, createdName=qingqingye, createdTime=Fri Nov 29 23:48:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569108, encodeId=78f3156910806, content=<a href='/topic/show?id=2651810889c' target=_blank style='color:#2F92EE;'>#肌钙蛋白T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81088, encryptionId=2651810889c, topicName=肌钙蛋白T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f7f15492758, createdName=huangdf, createdTime=Thu Sep 05 12:53:00 CST 2013, time=2013-09-05, status=1, ipAttribution=)]
    2013-11-29 qingqingye

    不错哈,飘过

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1721653, encodeId=45aa1e216534c, content=<a href='/topic/show?id=39d6915e9bf' target=_blank style='color:#2F92EE;'>#诊断价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91579, encryptionId=39d6915e9bf, topicName=诊断价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c7d33065043, createdName=medscijoin, createdTime=Thu Apr 10 11:53:00 CST 2014, time=2014-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900415, encodeId=16751900415c1, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Oct 27 22:53:00 CST 2013, time=2013-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6310, encodeId=58de631046, content=不错哈,飘过, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq6oFDfbfbCR2QaXr43JZleficjricO9bqaynTice57nB7xlLgg7tXtX5Y7RdTrC6pjWbuiaJ5RLVvib8w/132, createdBy=0c4390618, createdName=qingqingye, createdTime=Fri Nov 29 23:48:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569108, encodeId=78f3156910806, content=<a href='/topic/show?id=2651810889c' target=_blank style='color:#2F92EE;'>#肌钙蛋白T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81088, encryptionId=2651810889c, topicName=肌钙蛋白T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f7f15492758, createdName=huangdf, createdTime=Thu Sep 05 12:53:00 CST 2013, time=2013-09-05, status=1, ipAttribution=)]

相关资讯

2013年ESC/EHRA心脏起搏和再同步指南更贴近临床实际

     6月25日,在希腊雅典举行的EHRA EUROPACE会议上,欧洲心脏学会(ESC)和欧洲心律协会(EHRA)联合发布了2013年心脏起搏和心脏再同步化治疗指南,该指南根据发病机制而非病因建立了缓慢性心律失常的分类系统。       为使大家更易获取相关信息,本版指南进行了重新设计。指南比

ESC 2013:减压手术可减少老年恶性卒中患者死亡和残疾(DESTINY Ⅱ研究)

2013欧洲卒中大会(ESC)上公布的DESTINYⅡ研究结果表明,减压手术可显著增加大脑中动脉(MCA)卒中所致大面积脑肿胀的老年患者的生存率。 主要研究者、德国海德堡大学的Werner Hacke博士报告称, 1年随访结果显示,接受偏侧颅骨切除术治疗的≥61岁患者生存率为57%,而接受标准重症监护的患者生存率为24%(P<0.001),且生存率提高并未导致严重残疾增加。 Werner Hack

ESH/ESC 2013动脉高血压管理指南

2013年指南的内容其他变化包括:1) 家庭血压监测以及门诊血压监测的越来越重要。2) 更着重于评估心血管疾病和其他疾病的总体危险因素。例如,大多数患有高血压的人,也有额外的风险因素,如器官损伤、糖尿病和其他心血管疾病危险因素。这些都需要在开始治疗之前以及随访期间一并考虑。3) 特别强调特殊人群,例如糖尿病患者、年轻人、老人,以及80岁以上年龄段患者的药物治疗,妊娠期女性也需要单独考虑。特别关注了

2013 EHRA/ESC 心脏起搏器和心脏再同步化治疗指南

    2013年指南是自2007年以来的第一次修订,有70名临床医生参与,包括18名专门从事心脏起搏与再同步的心脏病专家组成的专家小组,还有26名该领域专家审阅文件,整个过程都在ESC实践指南(CPG)委员会的监督下进行。       指南第一部分探讨了心律失常患者的起搏适应证;第二部分探讨了心力衰竭患者的

ESC 2013:优化卒中后治疗策略使痴呆风险减半

据第22届欧洲卒中大会发布的一项观察二级预防策略长期影响的研究称,卒中患者经过优化降压,抗血栓,降血脂药物治疗后认知功能障碍可明显减轻。优化抗凝剂使用后降低认知功能障碍的相对危险度为0.8,最佳双重降压治疗,双重抗血小板治疗,降脂治疗降低认知功能障碍相对危险度分别为0.8,0.9,0.9,和0.9。研究者伦敦国王学院Abdel Douiri博士说,“联合使用抗高血压药,抗血栓药物及降脂药物可使认知

吴永健:ESC经导管去肾神经支配术专家共识解读

作者:何喆 吴永健(阜外心血管病医院) 经导管肾去神经支配术(renal denervation,RDN)是一种新兴技术,可显著且安全地降低顽固性高血压患者交感神经活性以及血压水平。经过几年的发展,结合多个临床试验结果的公布,2013年欧洲心脏病学会(ESC)及欧洲经皮心血管介入协会(EAPCI)专家组联合制定《ESC经导管去肾神经支配术专家共识》,从病理生理学、有效性及安全性的临床